Results 251 to 260 of about 644,115 (313)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

American journal of hematology/oncology, 2012
S. Kaatz, P. Kouides, D. Garcia, A. Spyropolous, M. Crowther, J. Douketis, A. Chan, A. James, S. Moll, T. Ortel, E. V. Van Cott, J. Ansell   +11 more
semanticscholar   +1 more source

Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase

, 2016
Masanori Tsujimoto, Gen Kuroyanagi, Rie Matsushima‐Nishiwaki, Yuko Kito, Yukiko Enomoto, Hiroki Iida, Shinji Ogura, Takanobu Otsuka, Haruhiko Tokuda, Osamu Kozawa, Toru Iwama   +10 more
openalex   +2 more sources

42 Incremental Economic Burden Associated With Major Bleeding among Atrial Fibrillation Patients Treated With Factor Xa Inhibitors

, 2016
Steve Deitelzweig, W. Richey Neuman, Melissa Lingohr-Smith, Brandy Menges, Judy Lin   +4 more
openalex   +1 more source

Cholesterol Crystal Embolism Induced by Direct Factor Xa Inhibitor: A First Case Report

, 2017
Hideaki Oka, Taro Kamimura, Yuki Hiramatsu, Kento Fukumitsu, Rei Iwata, Mika Kondo, Yutaro Hirashima, Seishi Aihara, Atsumi Harada, Kazuhiko Tsuruya   +9 more
openalex   +1 more source

Low-molecular-weight heparin is associated with lower venous thromboembolism events than factor Xa inhibitors in patients with severe blunt trauma: a cohort study from the Trauma Quality Improvement Program. [PDF]

Int J Surg
Chan SY, Huang JF, Cheng CT, Hsu CP, Liao CH, Fu CY.   +5 more
europepmc   +1 more source

Clotting and other plasma factors in septicemia [PDF]

, 1980
Fritz, Hans, Jochum, Marianne, Peeters, Hubert, Schießler, Hans, Witte, J.   +4 more
core  

Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach. [PDF]

Cardiovasc Drugs Ther
Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Mikus G, Meid AD, Haefeli WE, Blank A.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis

The Annals of Pharmacotherapy, 2020
Background: Clinical practice guidelines recommend that cerebral venous thrombosis (CVT) be managed with long-term anticoagulant therapy using warfarin or low-molecular-weight heparin (LMWH) for 3 to 12 months.
Marissa Z Powell, Kathryn Tremolet de Villers, K. Schwarz, D. Case, T. Trujillo   +4 more
semanticscholar   +1 more source